ObsEva Ends Recruitment In Second Uterine Fibroids Study
Zacks Investment Research | Jul 08, 2019 06:02AM ET
ObsEva SA (NASDAQ:OBSV) announced the completion of patient recruitment in its second pivotal phase III study, PRIMROSE 1, evaluating oral gonadotropin releasing hormone (GnRH) receptor antagonist, linzagolix, for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). Uterine fibroids are common non-cancerous tumors that grow within the muscular wall of the uterus.
PRIMROSE 1 will randomize about 500 patients who are diagnosed with HMB associated with UF. The patients will receive either a once daily dose of 100 mg or 200 mg of linzagolix, or placebo. Primary endpoint of PRIMROSE 1 is a clinically meaningful and statistically significant reduction in menstrual bleeding, as assessed by the alkaline hematin method, which is a validated, quantitative measurement of menstrual blood loss. Six-month primary endpoint data from the study are anticipated in the first half of 2020.
The company is also conducting another phase III study, PRIMROSE 2, simultaneously in the United States and Europe. The study is testing the same treatment arms at 102 sites, where about 500 patients have also been randomized. The company expects to report six-month primary endpoint data from the study in the fourth quarter of 2019.
The company’s shares have declined 11.5% year to date against the industry ’s growth of 4.3%.
We remind investors that another pharma company, AbbVie Inc. (NYSE:ABBV) , is also evaluating elagolix for uterine fibroids. The candidate is in phase III studies and the company expects to file a new drug application this year.
Zacks Ranks and Stocks to Consider
ObsEvacurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Applied Genetics Technologies Corp. (NASDAQ:AGTC) and Acorda Therapeutics Inc. (NASDAQ:ACOR) . While Applied Genetics sports a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). You can see .
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 90 days. The company surpassed estimates in three of the trailing four quarters, with average positive surprise of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.16 to $3.09 for 2020 in the past 60 days. The company outpaced estimates in the trailing four quarters, the average being 79.32%.
Get The News You Want
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.